Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia

C Simon Sebastian, William Glazer, Peter F Buckley

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.

Original languageEnglish (US)
Pages (from-to)329-342
Number of pages14
JournalCurrent Medicinal Chemistry
Volume11
Issue number3
DOIs
StatePublished - Feb 1 2004

Fingerprint

Antipsychotic Agents
Schizophrenia
Drug therapy
Therapeutics
Placebos
Availability
Pharmacology
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. / Sebastian, C Simon; Glazer, William; Buckley, Peter F.

In: Current Medicinal Chemistry, Vol. 11, No. 3, 01.02.2004, p. 329-342.

Research output: Contribution to journalReview article

@article{690c5f7e79d84fc5bad160a345974dfe,
title = "Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia",
abstract = "Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.",
author = "Sebastian, {C Simon} and William Glazer and Buckley, {Peter F}",
year = "2004",
month = "2",
day = "1",
doi = "10.2174/0929867043456025",
language = "English (US)",
volume = "11",
pages = "329--342",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia

AU - Sebastian, C Simon

AU - Glazer, William

AU - Buckley, Peter F

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.

AB - Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=1242329380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242329380&partnerID=8YFLogxK

U2 - 10.2174/0929867043456025

DO - 10.2174/0929867043456025

M3 - Review article

C2 - 14965235

AN - SCOPUS:1242329380

VL - 11

SP - 329

EP - 342

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 3

ER -